Taolan Zhang*
Hillary Fitzgerald*, Harkiran Sandhu, Claudio Tombazzi, Danika Paulo, Stacey Tillman, Sumathi Misra, Hamid Shah and Mohana Karlekar
Purpose: Poorly controlled pain is a significant quality of life issue for patients with advanced cancer. Patients often suffer from uncontrolled pain or intolerable side effects of treatment despite receiving multi-modal care with stepwise escalation of opioids. Interventional procedures impacting central pain pathways have demonstrated promise in treating pharmacologically intractable cancer pain and may be underutilized, especially in patients with escalating opioid use. The aim of this study was to assess effectiveness of bilateral anterior cingulotomy a minimally invasive neurosurgical procedure in patients with refractory malignant cancer pain through describing opioid use trends pre- and post-procedure and by comparing pain scores.
Methods: This is a retrospective review of a case series of six patients with refractory malignant pain who underwent bilateral anterior cingulotomy. Response to procedure was measured by percent change of pain scores and average daily opioid dose reduction. In addition, demographics, oncologic history, discharge disposition, survival time post-procedure, and complications were reported.
Results: Six unique patients underwent seven total procedures between 2019-2022. Average daily OME (oral morphine equivalent) dose 48 hours prior to procedure was 4411 mg. At discharge, average daily OME dose was 250 mg, an 89% dose reduction from 48 hours prior to procedure. Pain scores reduced by 43% during this same time period.
Conclusion: Cingulotomy effectively reduced pain scores with a concurrent reduction in opioid dosing in our cohort of patients with medically refractory malignant cancer pain. Further research is warranted to identify advanced cancer patients who may benefit most from this procedure and inform clinical adoption.
Colorectal malignancy (CRC) is the third driving reason for disease related demise in the United States, with an expected 135 430 new cases and 50 260 malignancy related passings yearly. Albeit the occurrence and infection explicit mortality has bit by bit declined in the course of recent many years, late investigations depict an upsetting pattern of an expanded frequency in more youthful (<50 years) people [1]. Most of patients determined to have metastatic colorectal malignant growth (mCRC) have serious sickness, except for those with oligometastatic illness, for which fruitful careful or ablative intercessions and foundational treatment has yielded 5-year and 10-year endurance paces of around 40% and 20%, individually. For any remaining patients with mCRC, the utilization of blend foundational treatments and ideal steady consideration has created significant enhancements in mortality, with the middle generally endurance (OS) presently surpassing 30 months. Notwithstanding, with a general 5-year endurance of just around 20%, there stays a lot of opportunity to get better with restorative strategies.In late years, there have been considerable headways in our comprehension of the convergence between have insusceptible reconnaissance and tumorigenesis.
Pembrolizumab, an enemy of customized passing 1 (PD-1) monoclonal neutralizer, has been supported as a first-line treatment for metastatic non-little cell cellular breakdown in the lungs (NSCLC), both as monotherapy [in patients with NSCLC communicating modified demise ligand 1 (PD-L1) and without sharpening EGFR/ALK genomic aberrations] and joined with platinum-based chemotherapy (pemetrexed–platinum in patients with metastatic nonsquamous NSCLC without sharpening EGFR/ALK genomic abnormalities; carboplatin and paclitaxel or grab paclitaxel protein-bound in patients with metastatic squamous NSCLC)
Yassine Smiti*, Brahim El Ahmadi, Zakaria Belkhadir, and Abdelilah Ghannam
Introduction: The installation of brachyherapy applicator is a painful invasive procedure requiring anesthesia. In this study, we propose to compare intravenous anesthesia with spontaneous ventilation to an intrathecal analgesic protocol with local anesthetics and fentanyl. The main objective was to demonstrate the superiority of spinal analgesia in terms of per and postoperative analgesia during patient mobilization for CT scan. We performed a randomized clinical trial for women patients ASA 1 and 2 programmed for brachytherapy, then we divided them into 2 groups. Group 1: Have benefited from intravenous anesthesia by propofol titration with fentanyl. Group 2: Benefited from spinal analgesia with bupivacaine 5 mg and fentanyl 25 mg. Then we collected demographic data, quality of anesthesia (Ramsay score for level of sedation, analgesia level by analogical visual scale score), hemodynamic and respiratory parameters, anesthetics events , duration of anesthetic acts, pain during mobilization.
Prostate malignant growth is the most widely recognized disease in men in the United Realm (UK), with more than 42,000 men being determined to have the condition each year. It is the second most normal malignant growth in men around the world. More than 1.1 million instances of prostate disease were analyzed in 2012. Ðe utilization of 3rostDte-6 Antigen (PSA) testing has prompted a general expansion in the frequency of prostate malignant growth rates. Its utilization has likewise brought about the early location of a huge number of limited prostate disease cases, which don't represent a danger to patients' wellbeing or lives.
Shaina Sedighim, Alexander Gaidarski, Talia Kamdjou, Simon Dadoun, Samantha Linhares*, Andrew Rosenberg and Mecker G. Möller
Maira Zia*, Elin Lundström, Johanna Mårtensson, Mark Lubberink, Aglaia Schiza and Anders Sundin
DOI: 10.37421/2577-0535.2022.7.006
RECIST 1.1 tumour size measurements on CT/MRI are the mainstay of cancer therapy monitoring. However, bone metastases are consistently difficult to evaluate for hormonal therapy response often escaping CT detection. This study aimed to assess dynamic and static [18F]sodium fluoride-([18F]NaF)-PET/MRI by combining standardized uptake value (SUV) and net influx rate (Ki) from PET with the apparent diffusion coefficient (ADC), proton density fat fraction (PDFF) and effective transverse relaxation rate (R2*) from MRI for monitoring hormonal therapy effect on bone metastases. In this prospective study, three breast cancer patients underwent a 60-minute dynamic whole-body [18F]NaF-PET/MRI before and after hormonal therapy. In PET images, pelvic and spine metastases (approx. n=10/patient) with high/intermediate uptake were delineated by applying an adaptive threshold algorithm to provide SUVmean and SUVmax. Pharmacokinetic modeling was performed and Ki was calculated using a two-tissue reversible model. VOI measurements of ADC, PDFF and R2* utilized the OLEA medical software. The changes between baseline and follow-up data were calculated, statistically analysed and utilized linear regression. [18F]NaF-PET/MRI provided a powerful method for monitoring hormonal therapy response in breast cancer bone metastases as reflected by decreases in SUV and Ki. MRI parameters showed changes consistent with therapy response, although only R2* reached statistical significance.
Richard Sullivan* and John Paulissen
DOI: 10.37421/2577-0535.2024.9.228
DOI: 10.37421/2577-0535.2024.9.229
Lung cancer remains a significant global health concern, accounting for a substantial number of cancer-related deaths. Understanding the causes, recognizing the symptoms, and implementing preventive measures are crucial for combating this disease. This research article aims to delve into the multifaceted aspects of lung cancer, shedding light on its causes, symptoms, and the importance of prevention strategies. By examining the latest scientific research and clinical findings, we hope to provide a comprehensive overview that will aid in raising awareness, early detection, and reducing the burden of lung cancer.
Lung cancer is a complex disease influenced by a combination of genetic, environmental, and lifestyle factors. This section provides an overview of the current global burden of lung cancer and highlights the need for research, prevention, and effective strategies to combat this deadly disease.
This section explores the primary causes of lung cancer, with a particular focus on tobacco smoke, including active and passive smoking. We delve into the harmful constituents of tobacco smoke, the mechanisms of carcinogenesis, and the increased risk associated with prolonged exposure. Furthermore, we discuss other risk factors, such as occupational hazards, air pollution, radon gas, and genetic predisposition, emphasizing their impact on lung cancer development.
DOI: 10.37421/2577-0535.2024.9.230
Lung cancer is a major cause of cancer-related deaths worldwide. However, advancements in medical imaging and diagnostic technologies have enabled the early detection of lung cancer, leading to improved patient outcomes and survival rates. This research article explores the significance of early detection in saving lives from lung cancer by examining current screening methods, diagnostic techniques, and their impact on patient care. It also discusses the challenges and future directions of early detection strategies for lung cancer.
Lung cancer is a global health concern, responsible for a significant number of cancer-related deaths each year. Late-stage diagnoses contribute to poor prognosis and limited treatment options. Therefore, early detection has become crucial in reducing mortality rates and improving patient outcomes. This article highlights the power of early detection in lung cancer, emphasizing its potential to save lives and enhance disease management.
This research article explores the power of early detection in saving lives from lung cancer by examining current screening methods, diagnostic techniques, and their impact on patient care. Various screening approaches, including chest X-rays, Computed Tomography (CT) scans, low-dose CT screening, and biomarkers, are discussed. Diagnostic techniques such as imaging, molecular and genetic testing, liquid biopsies, and artificial intelligence are also explored. The article highlights the positive impact of early detection on patient care, including improved survival rates, informed treatment decision-making, and reduced healthcare costs.
Challenges in early detection, such as false positives, accessibility, and education, are addressed. Finally, the article discusses future directions and innovations in early detection strategies, including advancements in imaging technology, integration of biomarkers and genetic testing, and personalized screening approaches. The power of early detection in lung cancer is underscored, emphasizing the need for widespread adoption and continued research to save more lives from this devastating disease.
Bsrat Tesfay Hagos* and Gebru Gebremeskel Gebrerufael
DOI: 10.37421/2577-0535.2024.9.231
Background: Breast Cancer (BC) is still a global public health issue that affects both industrialized and developing nations. It is the type of cancer that affects women most frequently in sub-Saharan African nations, particularly in Ethiopia. Despite the overwhelming difficulty, Ethiopian researchers have not yet identified the factors linked to mortality. Aside than that, there aren't many studies in this field. Therefore, the main goal of this analysis was to identify the most important factors that contributed to BC patients in Northern Ethiopia having shorter survival times.
Methods: 146 women in Northern Ethiopia who had BC were the subjects of an institutional-based retrospective cross-sectional study design that ran from September 12, 2015, to March 9, 2019. The STATA 14 program was used to conduct the statistical analysis. In order to identify predictors, a log-normal regression model and the Kaplan-Meier curve were both used.
Results: In Northern Ethiopia, the overall death rate prevalence was 18.5%. Retrospective monitoring of the chosen patients lasted an estimated 28.12 months on average. The age range of patients was 23-78 years with a median of 48 years. The multivariable Lognormal model analysis revealed, being distant metastatic ATR=0.52, CI=(0.341, 0.787), regional metastatic (ATR=0.63, (0.423, 0.924)), age (ATR=0.98, 95% CI: (0.968-0.997), baseline tumor size (ATR=0.98, 95% CI: (0.968, 0.996), clinical stage IV ATR= 0.48, 95% CI: (0.297-0.789), illiterate ATR=0.52, 95% CI: (0.325-0.823), and Rural residence ATR=0.68, 95% CI: (0.516-0.904) were found to be critical risk factors of time to death breast cancer patients.
Conclusion: The prevalence fatality rate among BC patients in Northern Ethiopia remains a serious public health issue, the research showed. Being clinical stage IV, distant and regional metastasis, illiteracy education level, baseline tumor size, rural residence, and old Age were discovered to be the most significant risk factors for patients' time to death. As a result, the government and other interested parties must address educational possibilities; raising awareness about the diagnosis of advanced disease and providing helpful advice on screening programs in a timely manner will lower the death rate and increase patient survival.
DOI: 10.37421/2577-0535.2024.9.232
Lung cancer remains a leading cause of cancer-related deaths worldwide. However, many cases of lung cancer are preventable through the promotion of healthy lifestyles and raising awareness. This research article aims to explore the significant role of healthy habits, such as tobacco control, diet modification, regular exercise, and early detection, in preventing lung cancer. It emphasizes the importance of public health campaigns, education, and policy interventions in creating a societal shift towards healthier choices and reducing the burden of lung cancer.
Lung cancer is a significant public health concern, accounting for a substantial number of cancer-related deaths globally. Despite advances in treatment, prevention remains the most effective strategy to combat this disease. This article highlights the importance of promoting healthy lifestyles and creating awareness to prevent lung cancer.
DOI: 10.37421/2577-0535.2024.9.233
Lung cancer is a leading cause of cancer-related mortality worldwide. Despite advancements in treatment modalities, the prognosis for lung cancer patients remains poor. However, recent developments in targeted therapies have shown promising results in revolutionizing lung cancer treatment. This research article aims to provide an overview of targeted therapies and their impact on lung cancer treatment. We discuss the underlying mechanisms of targeted therapies, current targeted therapy options, challenges, and future directions in this rapidly evolving field.
Lung cancer is a complex disease with diverse molecular subtypes, and traditional treatment approaches such as surgery, chemotherapy, and radiation therapy have limitations in effectively managing advanced stages of the disease. Targeted therapies, which focus on specific molecular alterations driving cancer growth, have emerged as a breakthrough in lung cancer treatment.
Targeted therapies exploit specific molecular aberrations in cancer cells, including gene mutations, amplifications, or rearrangements. These alterations may activate signaling pathways involved in tumor growth and survival. By inhibiting these aberrant molecular targets, targeted therapies aim to disrupt tumor growth and improve patient outcomes.
DOI: 10.37421/2577-0535.2024.9.234
Lung cancer remains one of the most prevalent and deadly cancers worldwide. The journey of a lung cancer patient is fraught with challenges, from diagnosis to treatment and beyond. However, empowering patients with knowledge and providing them with adequate support can greatly enhance their ability to navigate this complex disease. This research article explores the significance of empowering lung cancer patients, highlighting the role of knowledge and support in improving patient outcomes and overall quality of life. It also discusses various strategies and resources that can be employed to empower patients throughout their lung cancer journey.
Lung cancer is a significant global health concern, accounting for a substantial number of cancer-related deaths annually. The journey of a lung cancer patient is multifaceted, encompassing diagnosis, treatment decision-making, treatment administration, side effect management, and survivorship. This article emphasizes the importance of empowering patients with knowledge and support throughout this journey to enable them to actively participate in their care and make informed decisions.
Lung cancer remains a significant global health challenge, with a high mortality rate and a substantial impact on patients and their families. Navigating the complexities of lung cancer, from diagnosis to treatment and survivorship, requires comprehensive support and knowledge empowerment for patients. Empowering lung cancer patients with information and support plays a crucial role in improving their outcomes, enhancing treatment decision-making, and ultimately improving their overall quality of life.
Journal of Cancer Clinical Trials received 95 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 